REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations Meeting Abstract
| Authors: | Nishio, M.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Heymach, J. |
| Abstract Title: | REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations |
| Meeting Title: | 2024 ASCO Breakthrough: A Global Summit for Oncology Innovators |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 23 Suppl. |
| Meeting Dates: | 2024 Aug 8-10 |
| Meeting Location: | Yokohama, Japan |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-08-10 |
| Start Page: | TPS219 |
| Language: | English |
| DOI: | 10.1200/JCO.2024.42.23_suppl.TPS219 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting abstract: TPS219 -- Also held virtually -- Source: CINAHL Plus with Full Text |
